{"retracted":false,"update":{"timestamp":1480550400000,"doi":"10.1136/gutjnl-2016-312444corr1","type":"correction"},"doi":"10.1136/gutjnl-2016-312444","journal":"Gut","publisher":"BMJ","title":"n Erratum:n Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohortn "}
